Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0598934 (tumor growth)
 58,965 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Macrophages require a plasma component, designated "recognition factor" (RF), for the expression of optimal function. The RF activity was profoundly depleted in plasma from patients with malignant disease, and the degree of depletion and the severity of the malignant state seemed to be related. Since experiments demonstrated that an active RF significantly inhibited tumor growth, clinical studies were initiated to investigate the influence of intratumor administration of an active RF fraction. Glucan, a potent macrophage activator, was also employed alone or combined with RF. These studies were undertaken to enhance the recognition of malignant cells by macrophages and to mobilize and activate macrophages intralesionally. The initial 9 patients studied had malignant melanoma, adenosquamous carcinoma of the lung, or carcinoma of the breast. Control and experimental lesions were injected; subsequently biopsies were performed at varying intervals for histologic evaluation. Always when glucan or glucan and RF fraction were administered intralesionally, the size of the lesion was strikingly reduced in as short a period as 5 days. This reduction was associated with necrosis of the tumor and a monocytic infiltrate. In small lesions, resolution was complete, whereas in large lesions, resolution was partial. The amount of glucan injected and the quantity of residual tumor appeared to be related. The induced necrosis of the tumor nodule was associated with an increase in plasma levels of circulating RF activity.
 ...
PMID:Macrophage-mediated destruction of human malignant cells in vivo. 112 50

The following four types of tubular carcinoma of the breast were identified as a result of the study of 39 cases: typical tubular carcinoma of the breast; tubular mammary carcinoma with ductal invasion; ductal invasive carcinoma with tubular structures predominating over more than half the area of section; ductal invasive carcinoma incorporating few tubular structures. A specific clinico-morphological picture and prognosis are peculiar to each type of carcinoma. Tubular carcinoma of the breast and ductal invasive tumor with predominant tubular structures have a favorable prognosis and a regional metastasis frequency of 23-28%, practically without distant metastases. Tubular carcinoma of the breast is considered an early form of ductal invasive carcinoma which develops into other histological patterns as tumor growth progresses.
 ...
PMID:[Tubular carcinoma of the breast (clinico-morphological characteristics)]. 299 Jan 6

Several prospective clinical trials have been conducted to investigate the efficacy of prophylactic ovarium ablation in the primary treatment of carcinoma of the breast. The results have varied and the follow-up periods have been rather short. A prospective randomized study was done at our institution from 1961 to 1966 to test the value of prophylactic oophorectomy in the treatment of carcinoma of the breast. The patients have now been studied for 17 to 22 years. Patients were randomized into two groups: a control group and a group treated by surgical castration. By December 1983 280 patients were evaluable, 154 in the control group and 126 in the oophorectomy group. One hundred and forty-nine patients died during the observation time. All but 11 patients underwent autopsy. There are no significant differences between the group regarding age, axillary node involvement, menstrual status, perinodal tumor growth and distribution in the different TNM stages. The results of the study did not demonstrate any significant differences in cure rate, survival time, recurrence free intervals or intervals between recurrence of the disease and death. The results were independent of nodal status, TNM classification and menstrual status of the patient. These findings do not support the use of prophylactic oophorectomy in the treatment of operable carcinoma of the breast in TNM Stages I and II, whereas no conclusion can be drawn regarding TNM Stage III as the number of patients in this stage is small.
 ...
PMID:Prophylactic oophorectomy in the treatment of carcinoma of the breast. 351 47

The poor prognosis of obese women with carcinoma of the breast has yet to find a satisfactory explanation. It is suspected that the hormonal milieu of these patients may favor tumor growth. This investigation explored the relationship between obesity, urinary estrogen excretion, and tumor estrogen receptors (ER) in women treated with mastectomy for carcinoma of the breast. The ER levels determined from the primary cancers of 129 women treated with mastectomy were compared with the obesity index (O.I.) of these patients, i.e., weight in pounds/height in inches. In addition, 24-hour total urinary estrogen determinations were performed in 30 postmenopausal women and compared with their O.I. and ER. A weak direct correlation was found between ER and O.I. in postmenopausal women. The urinary estrogens of postmenopausal women were correlated directly with obesity index, but no relationship could be established between urinary estrogens and the ER content of breast cancers. It is concluded that the excess estrogen production of obese women may be responsible for their poor prognosis by promoting tumor growth. The high tumor ER concentrations associated with obesity suggest a high frequency of hormonally sensitive tumors.
 ...
PMID:Obesity, estrogen production, and tumor estrogen receptors in women with carcinoma of the breast. 683 4

Deletion of certain chromosomal regions can be demonstrated in malignant cells. Chromosome 16q is one of the regions where allelic loss is frequently detected in carcinoma of the breast and many other tumors, suggesting that gene(s) which retard tumor growth may exist here. To elucidate the clinicopathological significance of chromosome 16q, loss of heterozygosity (LOH) was investigated using microsatellite polymorphism analysis in 58 patients with endometrial lesions (50 with endometrial carcinoma and 8 who had hyperplasia with or without atypia). When 11 regions of chromosome 16q were examined, LOH was found in 20 patients with carcinoma (40%) and none of the patients with hyperplasia. The tumors of 9 of the 20 patients (45%) showed total loss of 16q, while the others (55%) showed partial deletion. Tumors with LOH were histologically less differentiated than those without LOH (P = 0.038, chi2 test). Patients with tumors showing LOH of 16q had a worse prognosis than those without LOH according to Kaplan-Meier survival analysis (P=0.0158, log-rank test). In addition, LOH of 16q showed a significant relationship to prognosis by Cox regression analysis. Deletion mapping of 16q demonstrated that two regions (16q22.1 and 16q22.2-23.1) were frequently involved. Patients with 16q22.1 LOH had a poorer prognosis than those with intact 16q22.1 (P=0.0003, log-rank test). These findings suggest that gene(s) of which defect is possibly related to the aggressiveness of endometrial cancer are localized on a limited region of 16q that includes 16q22.1.
 ...
PMID:Allelic loss of chromosome 16q in endometrial cancer: correlation with poor prognosis of patients and less differentiated histology. 904 49

The conservative treatment of carcinoma of the breast pursued since 1987 at the Gynecological Clinic of St. Elisabeth's Hospital in Saarlouis has resulted in a steady increasingly in the application of local flapping techniques, tumor-adapted reductive or mastoplastic procedures and latissimus dorsi flaps. A total of 446 breast tumors were removed by surgery and the breast preserved in 198 cases (= 44.4%). In 151 of these, the plastic correction of the defect was performed simultaneously. Transposition flaps (37 cases), rotation flaps (28 cases), modified reductive and mastoplastic techniques (71 cases), and latissimus flaps (15 cases) were applied, depending on the individual situation. In 22 cases a secondary operation was required: in 7 cases a mastectomy (5 cases of multifocal tumor growth, 1 flap necrosis during chemotherapy and 1 local recurrence), in 5 cases an excision biopsy owing to suspected recurrence with granuloma and in two cases a correction of the mamillary localization. 5 patients underwent an adaptive reduction of the healthy breast. The cosmetic results were: in 97 cases (65%) excellent or good, only 9 (6%) were evaluated by the operators as poor. Local recurrences were observed in 5 patients. These methods are intended to combine the oncological advantages of Veronesi's QUART principle (quadrantectomy, axillary dissection, radiation therapy) with improved cosmetics results, making it possible to operate larger tumors and smaller breasts with a satisfactory outcome.
 ...
PMID:[Plastic reconstructive surgical methods in breast saving therapy of breast carcinoma: our concept of modified quadrantectomy]. 953 5

Transforming growth factor-beta (TGF-beta) and interleukin 10 (Il-10) are cytokines that have a strong immunosuppressive ability. Their secretion by tumor cells is able to suppress an immunological response against tumor. Both factors have been shown to enhance tumor growth in glioblastomas and carcinoma of the breast. We determined the expression pattern of TGF-beta and Il-10 in squamous cell carcinomas of the head and neck (HNSCC) and a possible association with tumor stage and their pre-treatment cytokine serum levels. Cytokine expression in primary tumors and metastases of 21 patients with HNSCC was investigated by immunohistochemistry. To assess the TGF-beta2 and Il-10 levels in tumor patients before therapy 49 serum specimens were analyzed by ELISA. TGF-beta2 was detected in 95% of all tumor tissues analyzed and Il-10 in 79% of all tumors. TGF-beta2 was localized in tumor cells and tumor borders, while Il-10 was preferentially found in peritumoral connective tissue. Metastasizing tumors showed elevated pretreatment serum levels for TGF-beta2 and Il-10. There was no correlation between TGF-beta2 and Il-10 expression in tumor tissue and pretreatment serum levels. Our data show that the majority of HNSCC analyzed express TGF-beta2 and Il-10. A correlation between pretherapy elevated cytokine serum levels and tumor grade was shown.
 ...
PMID:[Cytokine expression of transforming growth factor-beta2 and interleukin-10 in squamous cell carcinomas of the head and neck. Comparison of tissue expression and serum levels]. 1055 Mar 71

Breast cancer is a heterogeneous group of diseases caused by differences in the biological, clinical, radiologic, and pathologic features of the different types of invasive carcinoma in the breast. The majority of invasive breast carcinomas are the invasive ductal or no special-type (NST) carcinomas. The rest of the invasive carcinomas are either nonductal carcinoma subtypes or special-type carcinomas, making up 20%-30% of all invasive carcinomas. The latter group comprises very different and distinctive types of cancer with imaging characteristics and challenges that are unique to each subtype. The invasive lobular carcinoma is the most common type of the nonductal carcinomas and can be difficult to detect on imaging because of the distinct pattern of tumor growth in sheets of single file cells with minimal desmoplastic reaction. The mucinous carcinoma of the breast contains extracellular mucin, secreted by the tumor cells. The mucin within these tumors result in imaging features that overlap with benign breast lesions, and may lead to misdiagnosis. Other rare and aggressive breast cancers include metaplastic breast carcinoma and inflammatory breast carcinoma. Both diseases have a poorer prognosis than invasive ductal carcinoma. This article will focus on the rarer non-NST carcinoma of the breast that can be a challenge to assess with imaging, partially related to the unique biology of these cancers.
 ...
PMID:Challenges and potential pitfalls in magnetic resonance imaging of more elusive breast carcinomas. 2178 24